OXB 203
Alternative Names: Aflibercept gene therapy - Oxford Biomedica; OXB-203Latest Information Update: 06 Oct 2021
At a glance
- Originator Oxford BioMedica
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Wet age-related macular degeneration